Peripal device approved in Europe for at-home peritoneal dialysis

Renal insufficiency is an expensive condition to treat due to the high cost of hospital dialysis treatment. Peripal AG, a Swiss startup, has received approval for the European market for its PeriSafe device for at-home dialysis.

Renal insufficiency is an expensive condition to treat due to the high cost of hospital dialysis treatment. Peripal AG, a Swiss startup, has received approval for the European market for its PeriSafe device for at-home dialysis.

Working with ETH Zurich, Peripal developed the device for the safe and easy connection in Peritoneal Dialysis. It’s addressing the two major complications in PD connection: the infection risk and the complexity of the therapy handling.

The majority of patients and their families would prefer therapy in the comfort of their own homes, but the risk of infection, increasing age, and the associated limitations are some of the reasons why ultimately very few patients choose to perform home dialysis.

“We developed the device in close collaboration with dialysis patients, so logically it is geared toward the needs of the people who actually use it.” said CEO Dr Sandra Neumann. 

Peripal was founded by Dr Sandra Neumann in 2015. It raised a Series A round in 2016 through StartAngels Network, as well as from Zürcher Kantonalbank and Aargauische Kantonalbank, and an A1 round in 2017.